{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-057020","form_type":"8-K","ticker":"CSBR","cik":"0000771856","company_name":"CHAMPIONS ONCOLOGY, INC.","filed_at":"2025-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.130113+00:00","generated_at":"2026-05-16T13:18:07.257148+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Champions Oncology Q2 revenue up 11% to $15M; net income $237K, adj EBITDA $843K; positive outlook","bullets":["Q2 total revenue $15.0M (+11% YoY); oncology services profit $7.8M, margin 52% vs 45%.","Net income $237K; adjusted EBITDA $843K; prior-year net income $728K, adj. EBITDA $1.1M.","Year-to-date revenue $29.0M (+5%); net loss $230K; adj. EBITDA $962K vs $3.2M prior.","Cash $8.5M, no debt; management on track for full-year revenue growth and positive adj. EBITDA.","R&D spend up 55% YoY, G&A up 57% on investments in data platform and business development."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-057020","json":"https://secwatch.observer/filing/0001628280-25-057020.json","markdown":"https://secwatch.observer/filing/0001628280-25-057020.md","text":"https://secwatch.observer/filing/0001628280-25-057020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771856/000162828025057020/0001628280-25-057020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771856/000162828025057020/csbr-20251215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:18:07.257148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}